Evidence map›Paper›PMID 40839193›Full record

ArticleBiochemical genetics2026

Extracellular Vesicle-Associated MicroRNA-25-3p Derived from Pancreatic Cancer Cells Promotes Hepatic Stellate Cell Activation and Enhances Cancer Progression.

Xuejiao Wu, Rui Shen, Zilin Yang, Yuming Tang, Jia Huang, Weiyan Yao

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuejiao Wu *Department of Anesthesiology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rui Shen *Department of Nursing, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zilin YangDepartment of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jing Er Road, Shanghai, China.
Yuming TangDepartment of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jing Er Road, Shanghai, China.
Jia Huang *Department of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jing Er Road, Shanghai, China. hj11693@rjh.com.cn.
Weiyan Yao *Department of Gastroenterology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jing Er Road, Shanghai, China. ywy11419@rjh.com.cn.ORCID http://orcid.org/0000-0001-8183-9497

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, mainly due to late diagnosis and early metastatic spread. The underlying mechanisms of pancreatic cancer metastasis, particularly the role of hepatic stellate cell (HSC) activation, are not fully understood. This study tried to find potential biomarkers for pancreatic cancer progression and prognosis by analyzing extracellular vesicle (EV)-associated miRNA profiles in plasma from pancreatic cancer patients and non-cancer controls. Functional assays, including transfection, western blotting, immunofluorescence, and enzyme-linked immunosorbent assay (ELISA), were used to assess the ability of the identified miRNA to activate HSCs and promote cancer progression. Our findings revealed that miR-25-3p was significantly upregulated in EVs derived from pancreatic cancer patients, correlating with increased metastasis and worse survival outcomes. EV-associated miR-25-3p from metastatic pancreatic cancer cells activated HSCs by regulating the expression of Krüppel-like factor 4 (KLF4). Additionally, activated HSCs secreted vascular endothelial growth factor (VEGF), further driving pancreatic cancer metastasis and progression. These results suggest that miR-25-3p could serve as a novel biomarker for pancreatic cancer progression and a potential therapeutic target to improve patient outcomes.

Indexed as

Extracellular VesiclesHepatic Stellate CellsMicroRNAsPancreatic NeoplasmsBiomarkers, TumorCell Line, TumorDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansKruppel-Like Factor 4Kruppel-Like Transcription FactorsMaleMiddle AgedVascular Endothelial Growth Factor ABiomarkers, TumorKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMicroRNAsMIRN25 microRNA, humanVascular Endothelial Growth Factor AExtracellular vesiclesHepatic stellate cellsMicroRNAsNeoplasm metastasisPancreatic neoplasms

Identifiers

PMID40839193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.